New test can differentiate between IBD, IBS and other bowel disorders
Thermo Fisher Scientific has announced the launch of EliA Calprotectin, the first fully-automated test for faecal calprotectin.
The test can differentiate inflammatory bowel diseases (IBD) such as Crohn‘s disease and ulcerative colitis from irritable bowel syndrome (IBS) and other functional bowel disorders (BD).
The test, which can be run on Phadia instruments available from Thermo Fisher, offers high-specificity, high-sensitivity and excellent predictive values to assist clinicians with early diagnosis.
“Today's tighter medical budgets require laboratories to become more efficient without compromising accuracy or negatively impacting patient care,” said Michael Haass. “By using the EliA Calprotectin test, labs can enable faster and more accurate diagnosis than standard tests currently used to distinguish IBD from IBS, and this ultimately delivers faster relief to patients in need.”
A faecal calprotectin test is effective in discriminating IBD from IBS and in helping monitor disease activity following diagnosis. It can also predict a relapse during clinical remission. The test has been shown to outperform blood tests such as CRP or ESR in discrimination and is effective in reducing the number of inconvenient and expensive endoscopic procedures.